Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 3

Blockade of PD-1/PD-L1 Axis May Improve NK-92 CellInhibition Caused by Mesenchymal Stem Cells

Pages
334–340
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the suppressive effects caused by MSCs may be significantly improved by blockingthe PD-1/PD-L1 axis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, it was aimed to investigate how the effects of Mesenchymal stem cells (MSCs) on the anti tumor properties of NK-92 cells change with programmed death-ligand-1 (PD-L1) blocking antibodies.
📊
Key Findings & Data:Methods: NK-92 cells were co-cultured with MDA-MB-231 breast tumor cells and MSCs.
💡
Conclusion & Impact:However, the suppressive effects caused by MSCs may be significantly improved by blockingthe PD-1/PD-L1 axis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, it was aimed to investigate how the effects of Mesenchymal stem cells (MSCs) on the anti tumor properties of NK-92 cells change with programmed death-ligand-1 (PD-L1) blocking antibodies. Methods: NK-92 cells were co-cultured with MDA-MB-231 breast tumor cells and MSCs. To evaluate the effect of anti PD-L1 antibodies, cells were cultured for 48 hours with and without the addition of 1, 5, and 10 µg/ml anti PD-L1antibody. IFN-γ, TNF-α, IL-10 and IDO levels of medium supernatants were determined by ELISA. CCK-8 kit was used toevaluate cytotoxic activity. Results: IFN-γ and TNF-α expressions of NK-92 cells co-cultured with MDA-MB-231 increased significantly, but thisincrease was significantly decreased in culture groups with MSCs. IDO expressions increased significantly in co-culturegroups with MSCs only. Cytotoxic effects of NK-92 cells were significantly reduced in culture groups with MSCs. How ever, the suppression effects caused by MSCs improved in the presence of anti-PD-L1 antibodies and in a dose depen dent manner. Conclusion: In our findings, we found that MSCs are a highly effective inhibitors, and the IDO enzyme they secrete mayplay a major role in this. However, the suppressive effects caused by MSCs may be significantly improved by blockingthe PD-1/PD-L1 axis.

🔖

Cite This Article

ÖZDEMİR, R. B. Ö., ÖZDEMİR, A. T., BERDELİ, A., KIRMAZ, C., VURAL, K., TUĞLU, M. İ., ÖZTATLICI, M., SÖNMEZ, P. K. (2022). Blockade of PD-1/PD-L1 Axis May Improve NK-92 CellInhibition Caused by Mesenchymal Stem Cells. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 3, 334–340. https://ajindex.com/articles/650391

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015
  2. 185–98. [CrossRef] 2. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009
  3. 126–44. [CrossRef] 3. Özgül Özdemir RB, Özdemir AT, Oltulu F, Kurt K, Yiğittürk G, Kırmaz C. A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues. Ann Diagn Pathol 2016
  4. 60–3. [CrossRef] 4. Ferns DM, Kema IP, Buist MR, Nijman HW, Kenter GG, Jordanova ES. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology 2015
  5. e981457. [CrossRef 5. Larrain MTI, Rabassa ME, Lacunza E, Barbera A, Cretón A, Segal-Eiras A, et al. IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis. Tumor Biol 2014
  6. 6511–9. [CrossRef] 6. Swart M, Verbrugge I, Beltman JB. Combination approaches with ımmune-checkpoint blockade in cancer therapy. Front Oncol 2016
  7. [CrossRef] 7. Navarrete-Bernal MGC, Cervantes-Badillo MG, Martínez-Herrera JF, Lara-Torres CO, Gerson-Cwilich R, Zentella-Dehesa A, et al. Biological landscape of triple negative breast cancers expressing CTLA-4. Front Oncol 2020
  8. [CrossRef] 8. Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, et al. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 2020
  9. [CrossRef] 9. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 2016
  10. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell Immunol 2017
  11. 1–10. [CrossRef] 11. Franquesa M, Hoogduijn MJ, Bestard O, Grinyó JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012
  12. [CrossRef] 12. Özdemir AT, Özgül Özdemir RB, Kırmaz C, Sarıboyacı AE, Ünal Halbutoğlları ZS, Özel C, et al. The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets. Cell Immunol 2016
  13. 108–15. [CrossRef] 13. Özdemir RBÖ, Özdemir AT, Sarıboyacı AE, Uysal